Antibodies in Cancer Treatment

Dear Colleagues,

Due to their high binding specificity, monoclonal antibodies (mAbs) embody the promise of precision medicine for treating patients with tumors. Antibodies recognizing tumor-restricted antigens have been explored in clinical trials. These have shown relatively limited response rates in unselected patient populations, most likely due to activation of alternative compensatory pathways and inter-/intratumoral heterogeneity in receptor expression and mutational status, associated with higher risk of local and systemic relapse.
There is an urgent unmet need for new antigen targets and modification of mAbs. The discovery of novel antigen targets, as well as the development of single-domain antibodies (nanobodies), bispecific antibodies and antibody–drug conjugates (ADCs) have become a focus to improve the performance of mAbs. Immunomodulatory antibodies and antibodies of alternative isotypes can also present a potential strategy to retain, recruit or differentially activate immune effector cells in tumor microenvironments, and facilitate tumor cell destruction.
This Special Issue will highlight promising mAb strategies that may provide the basis for further translational investigations, particularly for patients who do not adequately benefit from currently available treatments.

Dr. Anthony Cheung
Dr. Heather J Bax
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.